Skip to main content

Advertisement

Table 4 The most common toxicities in patients with BRAF V600E-mutated mCRC in standard therapy group (treated with cytotoxic doublets with or without bevacizumab) and intensive therapy group (treated with modified FOLFOXIRI regimen)

From: Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study

Toxicity (NCI-CTC grade) Standard therapy group (n = 50) Intensive therapy group (n = 6)
Grade 1 Grade 2 Grade 3 Grade 4 Grade 1 Grade 2 Grade 3 Grade 4
Thrombocytopenia 18 (36.0) 1 (2.0) 0 (0) 0 (0) 0 (0) 1 (16.7) 0 (0) 0 (0)
Anemia 15 (30.0) 14 (28.0) 3 (6.0) 0 (0) 0 (0) 2 (33.3) 0 (0) 0 (0)
Nausea 15 (30.0) 9 (18.0) 0 (0) 0 (0) 2 (33.3) 1 (16.7) 0 (0) 0 (0)
Peripheral neurotoxicity 13 (26.0) 14 (28.0) 0 (0) 0 (0) 2 (33.3) 1 (16.7) 0 (0) 0 (0)
Astenia 11 (22.0) 11 (22.0) 1 (2.0) 0 (0) 0 (0) 1 (16.7) 0 (0) 0 (0)
Vomiting 10 (20.0) 5 (10.0) 0 (0) 0 (0) 2 (33.3) 0 (0) 0 (0) 0 (0)
Diarrhea 10 (20.0) 4 (8.0) 0 (0) 0 (0) 2 (33.3) 1 (16.7) 0 (0) 0 (0)
Neutropenia 10 (20.0) 13 (26.0) 15 (30.0) 6 (12.0) 0 (0) 2 (33.3) 1 (16.7) 1 (16.7)
Stomatitis 9 (18.0) 5 (10.0) 0 (0) 0 (0) 1 (16.7) 0 (0) 0 (0) 0 (0)
Hypertension 3 (6.0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Hemorrhage 3 (6.0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
  1. All values are presented as number of patients followed by percentage in parentheses
  2. FOLFOXIRI 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan, NCI-CTC National Cancer Institute Common Toxicity Criteria